key: cord-0921817-r6gz6c8w
authors: Fourati, Slim; Langendorf, Céline; Audureau, Etienne; Challine, Dominique; Michel, Justine; Soulier, Alexandre; Ahnou, Nazim; Désveaux, Isaac; Picard, Oriane; Ortonne, Valérie; Gourgeon, Aurélie; Mills, Clair; Hémery, François; Rieux, Claire; Pawlotsky, Jean-Michel; Malou, Nada; Chevaliez, Stéphane
title: Performance of Six Rapid Diagnostic Tests for SARS-CoV-2 antigen detection and Implications for Practical Use
date: 2021-07-25
journal: J Clin Virol
DOI: 10.1016/j.jcv.2021.104930
sha: 3ce5c750da256b496685efd0ab2962237a767adb
doc_id: 921817
cord_uid: r6gz6c8w

BACKGROUND Direct detection of SARS-CoV-2 viral proteins in nasopharyngeal swabs using lateral flow immunoassays is a simple, fast and cheap approach to diagnose the infection. AIMS AND METHODS The performance of 6 SARS-CoV-2 antigen rapid diagnostic tests has been assessed in 634 hospitalized patients or outpatients including 297 patients found to be positive for SARS-CoV-2 RNA by means of RT-PCR and 337 patients presumed to be SARS-CoV-2 RNA-negative. RESULTS The specificity of SARS-CoV-2 RDTs was generally high (398.5%). One assay had a lower specificity of 93.2%. The overall sensitivity of the 6 RDTs was variable, from 32.3% to 61.7%. Sensitivity correlated with the delay of sampling after the onset of symptoms and the viral load estimated by the Ct value in RT-PCR. Four out of 6 RDTs tested achieved sensitivities 380% when clinical specimens were collected during the first 3 days following symptom onset or with a Ct value ≤25. CONCLUSIONS The present study shows that SARS-CoV-2 antigen can be easily and reliably detected by RDTs. These tests are easy and rapid to perform. However, the specificity and sensitivity of COVID-19 antigen RDTs may widely vary across different tests and must therefore be carefully evaluated before releasing these assays for realworld applications.

 Performance of RDTs has been assessed in more than 600 individuals 27  The rate of success of the 6 RDTs was high (from 99.1% to 100%) 28  The specificity of SARS-CoV-2 RDTs was generally high (98.5%) 29

 The overall sensitivity of the 6 RDTs was variable 30 of insufficient cellular materials in the NPS sample [1] . However, RT-PCR is costly and must 48 be performed in certified biology laboratories, while requiring technical skills and 49 sophisticated equipment. Most SARS-CoV-2 RNA assays and platforms require batches of 50 multiple specimens within a single run, while at least 4 to 6 hours are required to complete 51 the analyses. Furthermore, because of the scale of the worldwide pandemic, intermittent 52 reagent and materials shortages limit COVID-19 diagnostic capacities. For all these reasons, 53

scaling-up RT-PCR for larger-scale screening will not be possible, especially in low-and 54 middle-income settings, emphasizing the need for easier, shorter and cheaper virus 55 detection methods. 56

Direct detection of SARS-CoV-2 viral proteins in NPS using lateral flow immunoassays 57 (SARS-CoV-2 antigen assays) is a simple, fast and cheap approach to diagnose the infection. 58 SARS-CoV-2 antigen assays generate individual results in less than 30 minutes and can be 59 performed at the patient's sampling site, outside of the clinical laboratory. Therefore, SARS-60

CoV-2 antigen tests may be used for individual diagnosis as well as for large-scale testing by 61 a variety of healthcare workers in decentralized settings, allowing for early detection and 62 isolation of infected individuals, with the aim of reducing community transmission. 63

Nevertheless, the sensitivity, specificity, positive and negative predictive values of SARS-CoV-64 2 antigen tests compared to RT-PCR must be known before recommending their use for such 65 purpose. 66

Objectives 68

This retrospective diagnostic case control study using a large number of frozen NPSs 69 aimed to evaluate the performance of 6 commercially available rapid diagnostic tests (RDT) 70

for SARS-CoV-2 antigen detection and to describe their potential integration into diagnostic 71 algorithms adapted to health systems and epidemiological contexts. 72

The performance of 6 SARS-CoV-2 antigen RDTs has been assessed in 634 75 symptomatic hospitalized patients or outpatients from the Henri Mondor university hospital. 76

They included: (i) 297 patients found to be positive for SARS-CoV-2 RNA by means of RT-PCR 77 between March and April 2020; (ii) 337 patients presumed to be SARS-CoV-2 RNA-negative 78 because they had been sampled between April and August 2019 (i.e., before the emergence 79 of SARS-CoV-2), including some who were positive for one or more other respiratory 80 pathogen(s) ( The results were read after 15-30 min by two independent laboratory investigators. 

The rate of success of the 6 RDTs was high, comprised between 99.1% and 100%. All for NG-test up to 61.7% (95%CI: 55.9%-67.3%) for AAZ COVID-VIRO. As shown in Table 4 (Table  175   4 ). In addition, the association between sensitivity and the delay of sampling after the onset 176 of symptoms was maintained after adjustment the viral load estimation ((Supplementary 177 The detection rates of BIOSENSOR Standard Q and AAZ COVID-Viro were 100% for samples 183 with a Ct value 20, and decreased to 92.5%, 61.3% and 12.0% (BIOSENSOR Standard Q) and 184 to 94.4%, 65.8% and 9.1% (AAZ COVID-VIRO) for Ct values 21-25, 26-30 and ≥31, respectively 185 (Table 4) . 186

The severity of the disease (mild versus severe/critical) did not appear to affect the 187 sensitivity of antigen detection compared to RT-PCR (Table 4) . In our study, SARS-CoV-2 antigen detection using lateral flow assay was globally less 212 sensitive for the diagnosis of infection than nucleic acid detection by means of a 2-target 213 molecular method. When compared to RT-PCR, antigen detection using RDTs was more 214 sensitive when the viral load was high (Ct ≤25, reported to correspond to SARS-CoV-2 RNA 215 levels higher than 10 6 copies/mL, a proposed threshold of transmissibility . Finally, RDTs were tested in a university hospital laboratory by highly 253 qualified and trained personnel, which may not reflect the situation with less well-trained 254 operators in the real world. The technical handling is however extremely simple after 255 minimal training. The use of fresh dry swabs with bigger cellular loads may increase the 256 sensitivity of these assays in proportions that need to be determined. Rapid assays were not 257 conducted within manufacturer requirements. 258

In conclusion, our study, based on a large number of well-characterized hospitalized 259 patients and outpatients with or without SARS-CoV-2 infection, shows that rapid diagnostic 260 tests are reliable tools for the rapid diagnosis of COVID-19 and the control of this pandemic. 261

These tests are easy and rapid to perform in the context of patient care. However, the 262 specificity and sensitivity of COVID-19 antigen RDTs may widely vary across different tests 263 and must therefore be carefully evaluated before releasing these assays for real-world 264 applications, including the diagnosis of early symptomatic infection, contact tracing and 265 large-scale screening campaigns. Our study indicates that some tests may lack specificity, 266 exposing to the risk of a high number of falsely-positive results. Some assays showed 267 excellent sensitivity for NSPs with high viral loads, indicating that these tests will be able to 268 identify the most contagious individuals without requiring RT-PCR and access to biology 269 laboratories, thereby playing a key role in interrupting the chains of contamination . 

A Review

Detection of 2019 294 novel coronavirus (2019-nCoV) by real-time RT-PCR

RealStar(R) SARS-CoV-2 RT-PCR kit RUO performances and limit of detection